The Within3 team was thrilled to attend this year’s Pharmaceutical Launch Excellence Summit – the world’s only event dedicated to pharma launch. On top of delivering our own workshop, TED Talk, and fireside chat at the event, we were lucky enough to attend some fascinating sessions and panel discussions during our three days in London. Here, we’ve collated five of our key takeaways from Pharma Launch Excellence 2025.
1. The definition of ‘launch excellence’ has fundamentally shifted
Summit attendees unanimously agreed that the definition of launch excellence itself has changed significantly. The consensus was that launches must evolve from linear projects to dynamic, intelligence-driven processes. Teams agreed that these processes must begin sooner, move faster, and rely on deeper cross-functional collaboration than the approaches the industry is currently familiar with.
These sentiments were echoed by Impatient Health’s Paul Simms during our opening-day fireside chat.
“Should launches continue to look like rocket launches? We spend years planning, we get every detail perfect, and then a little bit of wind is wrong on launch day and the whole thing blows up in a big firework of epic proportions. That’s the model we’re used to. The model that we could move towards is more like driving a car – a different kind of journey… Maybe you have technology, a GPS in the car that helps you decide on the best route.”
– Paul Simms, Impatient Health
Launch Intelligence™ is that GPS – supporting pharma launches through continuous insight reporting and actionable intelligence.
2. Launches must start earlier – years earlier
Throughout Pharma Launch Excellence 2025, speakers repeatedly emphasized how launch planning must begin 3–5 years prior to a new compound actually hitting the market. There was also universal agreement that the first six months post-launch effectively determine long-term commercial success. Teams require clear market visibility if they are to effectively adapt to market trends and fluctuations post launch – and at the moment, they aren’t getting that visibility.
Within3 Founder and CEO Lance Hill spoke about how a lack of market understanding can derail even the strongest launch plans.
“Launches fail either because there’s no data coming in, and we’re traveling along paths thinking ‘no news is good news’, or because we’re missing data.”
– Lance Hill, Within3
The solution is to deliver insight streams early, via a clear, real-time market view – empowering teams to anticipate market changes and rapidly align around a unifying strategy.
3. AI moves beyond buzzword
AI was everywhere at Pharma Launch Excellence 2025. But where the technology might previously have been dismissed as a buzzword, it’s now being assessed with a practical lens. Less “what might AI deliver in the future” and more “how can AI help deliver launch excellence right now?”
Applications, including scenario simulations, real-time risk modeling, and cross-functional signal routing, were discussed by speakers and attendees alike, reflecting the idea that teams want to move away from reactive decision-making and toward proactive, predictive, and probability-driven launch strategies.
Within3’s Jason Smith, CTO, AI & Analytics and Ian McKinnon, Global Head of Consulting, covered these topics in their popular workshop The Metrics, Or The Truth. Some workshop participants hoped AI would provide “a single source of truth” by integrating data sets and breaking down silos, while others discussed the need for AI tools to integrate with existing technologies and workflows to enhance productivity.
The challenges raised in the workshop point to a clear opportunity: launch-focused AI is already capable of meeting these needs. Launch Intelligence™ creates an intelligent layer across existing tools and technologies, bringing siloed data together into a single, actionable view – accelerating decision-making by channeling critical insights to the right teams at the right times.
4. Agility is becoming the new operating model, with Launch Intelligence™ as a catalyst
There was wide recognition that there are two approaches to launch: the ‘old way’ and the ‘new way’. Attendees discussed how the ‘old way’ has become obsolete, and that outdated playbooks based around slide decks, manual reporting, and disconnected data must be scrapped in favor of:
- Rapid response mechanisms
- Enhanced signal detection
- Fluid, real-time collaboration
- Data integration
- Continuous insights
- Earlier foresight
- Prediction versus reaction
In his TED Talk Decoding Data to Enable Launch Success, Within3’s Managing Director, Global Head of Consulting Ian McKinnon explained what the ‘new way’ might look like when powered by Launch Intelligence™:
“Think of the data as being integrated and not separate. Multiple data streams have come in – congress, social feeds, field notes – and we’re using AI to summarize thousands of data points against key insight topics so you get the mission-critical insights that ensure your launch is successful.”
– Ian McKinnon, Within3
5. Success stories show that teams can win despite imperfect conditions
One of the lasting takeaways from Pharma Launch Excellence 2025 is not to write launches off too early. While that six-month statistic surfaced again and again – the idea that the first half-year is critical in determining long-term success – multiple case studies proved this threshold can be overcome. These success stories showed that despite lean teams, licensing complexity, limited resources, and last-minute pivots, it’s still possible to perform a strong turnaround after the six-month mark has passed.
However, the lesson here isn’t that the idea of the first six months being an indicator of long-term performance is wrong. It’s more that course correction after this point is possible – but only with the right intelligence in place.
In his TED Talk, Ian McKinnon shared a case study of the launch of a gastroenteritis treatment that had been linked to adverse patient outcomes. Using Launch Intelligence,™ the team identified how various comorbidities were delaying diagnosis and affecting treatment rates. The Within3 platform also provided a report with recommended action steps for the client team. With these insights, the team was able to swiftly address the issue – improving patient outcomes and turning the launch trajectory around.
These key takeaways are a distillation of a single, consistent idea – the idea that the definition of launch excellence is changing just as rapidly as the paths we take to get there. AI is positioned to help launch teams break down silos, inform launch strategy, and gain deep market understanding at speed and at scale. If you’re ready to achieve launch excellence in 2025, schedule a demo of our AI-powered Launch Intelligence™ today.
